Medical condition
Cancer Treatment
Cancer Treatment is a medical condition tracked by NovaPharmaNews across 2 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- trastuzumab (HERZUMA) Antineoplastic and immunomodulating agents (L01)
- trifluridine (LONSURF) Antineoplastic and immunomodulating agents (L01)
Latest Cancer Treatment news
AstraZeneca's Camizestrant: Navigating Divergent Regulatory Paths for Breast Cancer Treatment
AstraZeneca's breast cancer drug, camizestrant, faced a significant regulatory divergence with CHMP approval in Europe contrasting with an FDA rejection. This split highlights evolving global regulatory landscapes and presents key considerations for pharmaceutical business development and investment strategies.
Ultra-Low Doses: A Game Changer for Cancer Treatment Access
Ultra-low doses of cancer treatments could significantly improve accessibility for patients in low-income regions. This article discusses recent developments and implications for the pharmaceutical industry.
China Approves HERNEXEOS for Lung Cancer Treatment
Boehringer Ingelheim's HERNEXEOS has received approval in China as an initial treatment for lung cancer, marking a pivotal moment in oncology. This development has far-reaching implications for the pharmaceutical industry.
Targeted Protein Degraders: A New Era in Cancer Treatment
This article examines the potential of targeted protein degraders in cancer therapy, focusing on KRAS elimination and its implications for the pharmaceutical industry.
FDA Approval for Datroway: Implications for Breast Cancer Treatment
The FDA has granted approval for Datroway, a significant development for breast cancer treatment by Daiichi Sankyo and AstraZeneca. This article explores the implications for investors and pharma teams.
Enhertu's Dual FDA Approvals: A Game Changer in Early Breast Cancer Treatment
Daiichi and AstraZeneca's Enhertu has received dual FDA approvals for early breast cancer, marking a significant milestone in oncology. This article explores the implications for investors and pharma teams.
NICE Approval for Imfinzi: Implications for Stomach Cancer Treatment
NICE's backing of Imfinzi for stomach cancer marks a significant milestone for AstraZeneca. This article explores the implications for investors and pharma teams.
Atara Biotherapeutics Receives FDA Complete Response Letter for EBVALLO Cancer Treatment, Faces Securities Class Action
Atara Biotherapeutics' EBVALLO cancer therapy receives FDA Complete Response Letter, delaying approval as company faces securities class action lawsuit deadline May 22, 2026.